The abiraterone acetate plus prednisone and prednisone-alone groups demonstrated a significant survival difference ( P = .034 ) ; surrogate distribution at 12 weeks differed by treatment ( P < .001 ) ; the discriminatory power of the surrogate to predict mortality was high ( weighted c-index , 0.81 ) ; and adding the surrogate to the model eliminated the treatment effect on survival .